公开(公告)号：US20230071283A1

公开(公告)日：2023-03-09

申请号：US16093758

申请日：2017-04-14

Applicant: Andrei Golosov ,  Carla Patricia Pinto Guimaraes ,  Gregory Motz ,  Michael C. Milone ,  Christoph T. Ellebrecht ,  Aimee S. Payne ,  Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Andrei Golosov ,  Carla Patricia Pinto Guimaraes ,  Gregory Motz ,  Michael C. Milone ,  Christoph T. Ellebrecht ,  Aimee S. Payne

IPC: C07K14/725

Abstract: Provided herein are fusion proteins including two protein domains separated by a heterologous protease cleavage site, wherein a first of the protein domains is a conditional expression domain. Thus, the fusion proteins comprise three essential elements: a conditional expression domain, a domain containing the protein of interest, and a protease cleavage domain separating the two. Also provided herein are methods for treating autoantibody and alloantibody-mediated diseases or conditions in a subject by targeting B cells with anti-B cell modified T cells. In one embodiment, a chimeric antigen receptor (CAR) modified T cell is selectively ablated in a subject after adoptive transfer. Pharmaceutical compositions comprising the temporally regulated CAR modified T cell are also described herein.

公开(公告)号：US20180125892A1

公开(公告)日：2018-05-10

申请号：US15727402

申请日：2017-10-06

Applicant: Barbara Brannetti ,  Jennifer Brogdon ,  Boris Engels ,  Brian Granda ,  Lu Huang ,  Ming Lei ,  Na Li ,  Jimin Zhang ,  Carla Patricia Pinto Guimaraes

Inventor： Barbara Brannetti ,  Jennifer Brogdon ,  Boris Engels ,  Brian Granda ,  Lu Huang ,  Ming Lei ,  Na Li ,  Jimin Zhang ,  Carla Patricia Pinto Guimaraes

IPC: A61K35/17 ,  A61K38/17 ,  C07K16/28 ,  C12N15/85 ,  A61P35/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.